Page 6 - Who

Omicron is not common cold, warns WHO, says not to take it lightly

Amid reports that Omicron has symptoms akin to a common cold, the World Health Organisation (WHO) on Wednesday warned that it is not a common cold and should not be taken lightly.

WHO still recommends 14-day quarantine for Covid-19 patients: Official

Although most people recover from COVID-19 within five to seven days of the onset of symptoms, the WHO still recommends a 14-day quarantine, an official from the organization said

Why is the IMF trying to be an aid agency?

Forceful conditionality is essential to establish financial stability and ensure that IMF's resources do not end up financing capital flight

'If we end inequity, we end COVID-19 pandemic', says WHO chief Tedros

As the world enters its third year of the COVID-19 pandemic, the WHO Director-General Tedros Adhanom Ghebreyesus said he was confident that the pandemic will end in 2022 "if we end inequity" together.

Covid: No science behind night curfews in India, says WHO's Swaminathan

There is no science behind night curfews when it comes to tackling the spread of Covid variants, WHO Chief Scientist Soumya Swaminathan has stressed

LIVE: Mumbai sees over 3,600 new Covid cases in a day; over 1,300 in Delhi

Mumbai posts 46% jump in daily cases; Delhi passes 1,000-mark after 7 months

Overall risk from Omicron Covid variant remains 'very high', says WHO

The overall risk related to the new variant of concern Omicron remains "very high", the WHO said as the world continues to witness the surge in global Covid-19 cases.

How may Omicron affect the recovery of the hospitality sector?

The world is ringing in New Year amid rising Covid infection. And so is the hospitality industry, which was hoping to recover losses with year-end revelry. Let's look at what it means for the sector

Explained: New easy-to-use Covid treatment pills come with a catch

Newly infected COVID-19 patients have two new treatment options that can be taken at home. But that convenience comes with a catch: The pills have to be taken as soon as possible once symptoms appear. The challenge is getting tested, getting a prescription and starting the pills in a short window. U.S. regulators authorized Pfizer's pill, Paxlovid, and Merck's molnupiravir last week. In high-risk patients, both were shown to reduce the chances of hospitalization or death from COVID-19, although Pfizer's was much more effective. A closer look: WHO SHOULD TAKE THESE PILLS? The antiviral pills aren't for everyone who gets a positive test. The pills are intended for those with mild or moderate COVID-19 who are more likely to become seriously ill. That includes older people and those with other health conditions like heart disease, cancer or diabetes that make them more vulnerable. Both pills were OK'd for adults while Paxlovid is authorized for children ages 12 and older. WHO SHOULD

Explained: What Covid-19 pandemic therapies are available in US?

The U.S. recently added two new weapons to its small arsenal against the coronavirus: pills that patients can take at home to treat COVID-19. The drugs from Pfizer and Merck join a handful of other therapies that have been shown to blunt the worst effects of the virus. But each treatment has different advantages and tends to work best for certain types of patients at different stages of the disease. Here's a look at the current COVID-19 drugs and how they are used: PILLS The prescription pills are the first COVID-19 therapies that don't require infusions or injections delivered by health professionals. The Food and Drug Administration authorized Pfizer's Paxlovid on Wednesday and Merck's molnupiravir on Thursday. Merck's drug is for adults with a positive COVID-19 test, early symptoms and who face the highest risks of hospitalization. Pfizer's is for anyone 12 and older who likewise face the highest risks of hospitalization. Pfizer's drug is likely to become the first-choice tre

LIVE: Govt is alert, taking proactive action, says PM at Covid review meet

Centre on Thursday in an advisory cautioned states to observe all precautions and don't let the guard down in view of the rise in Omicron variant cases

Blanket booster drives risk prolonging Covid-19 pandemic, says WHO chief

WHO Director-General Tedros Adhanom Ghebreyesus said the priority must be to reduce deaths and help all countries meet minimum vaccination targets

Still too soon to say if Omicron more transmissible than Delta: WHO

The UN agency's experts regularly meet drugmakers to discuss the best composition of COVID-19 vaccines as the industry looks at whether shots need to be tweaked to tackle the coronavirus.

LIVE: Kerala sees 9 more Omicron cases, 4 in Jaipur; India's tally now 226

Meanwhile, Haryana decides to allow only fully vaccinated people at public places; Delhi bans gatherings for Christmas, New Year celebrations

'Another storm coming': WHO warns of Omicron variant surge in Europe

Omicron has been detected in at least 38 of the WHO European region's 53 members

WHO's chief Tedros Adhanom calls on world to end Covid-19 pandemic in 2022

Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), has called on the world to pull together to end the Covid-19 pandemic within the next year.

Top Headlines: WHO warns on Omicron; public health infra priority in 2022

Business Standard brings you the top headlines at this hour.

Covid-19: WHO sounds warning over fast-spreading Omicron variant

Says Omicron is evading some immune responses; China must share more data on virus origins

India among largest contributors of global solidarity trial: WHO on Covid

WHO Chief Scientist Dr Soumya Swaminathan said India is one of the largest contributors of the global solidarity trial for Covid vaccines

Omicron cases doubling in 1.5-3 days in areas with local spread: WHO

However, it is unclear if this is due to the virus' ability to evade immunity, its inherent increased transmissibility or a combination of both, the WHO said in an update